electroCore, Inc.
NASDAQ:ECOR
Net Margin
electroCore, Inc.
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
electroCore, Inc.
NASDAQ:ECOR
|
48.4m USD |
-54%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
220.3B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
181.1B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
151.3B USD |
11%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
142.7B USD |
13%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
115.7B USD |
13%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
66.5B USD |
8%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
57.8B EUR |
9%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
42B USD |
77%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
291.6B CNY |
33%
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
37.3B USD |
10%
|
electroCore, Inc.
Glance View
electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 52 full-time employees. The company went IPO on 2018-06-22. nVNS is a platform for bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The firm is providing gammaCore device for the treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults. gammaCore permits patients to self-administer doses of nVNS on an as-needed basis for treatment of prevent multiple types of headache pain via the vagus nerve. The gammaCore therapy is also used to treat primary headache, including migraine, cluster headache (CH), hemicrania continua and paroxysmal hemicrania (PH) and coronavirus (COVID-19).
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on electroCore, Inc.'s most recent financial statements, the company has Net Margin of -54.4%.
You don't have any saved screeners yet